Engineered heart muscle allografts for heart repair in primates and humans
Jebran AF, Seidler T, Tiburcy M, Daskalaki M, Kutschka I, Fujita B, Ensminger...
Your Trusted NAMs Partner
Accelerating the New Approach Methods (NAMs)-Driven Revolution in Drug Discovery — innovative, human-relevant technologies that reduce reliance on animal testing and enable faster, safer, and more cost-effective drug development.
Revolutionizing Drug Discovery with iPSC and AI
Greenstone Biosciences is revolutionizing drug discovery. We leverage cutting-edge human iPSC-based New Approach Methods (NAMs) using 3D organoids and advanced human micro-physiological systems, and Artificial Intelligence (AI) technologies.
About Us
Greenstone Biosciences is a biotech innovator based in Stanford Research Park. We operate at the intersection of regulatory change and technological advancement, driven by the belief that New Alternative Methods, or New Approach Methods (NAMs)—and other human-relevant models—are reshaping the future of medicine. Building on this foundation, we combine:
Our Services
Greenstone Biosciences offers advanced iPSC-based solutions and AI-powered platforms to accelerate drug discovery. From patient-derived models to high-throughput screening and organoid assays, our services deliver human-relevant insights that drive safer, more effective therapies.
PBMC Collection and iPSC Reprogramming
Custom Differentiated iPSCs
Genetically Engineered iPSCs
High-throughput Drug Discovery
Cell Village
Clinical Trial in a Dish
CARTOX (hERG Toxicity Assay)
Hepatotoxicity Screen
Functional Assays of Gut Barrier Integrity and Disease Modelling
Pancreatic Islet Organoid – Glucose Sensitivity
Our Products
Innovative Cellular Models for Research & Therapy
Unlock the power of human biology with our advanced platforms. Greenstone Biosciences offers hiPSC-derived cells and organoids that accelerate translational research, reduce clinical risks, and drive the development of safer, more effective therapies.
hiPSC-Derived Cells
- Unlimited self-renewal capacity
- Patient-specific disease modeling
- High relevance for drug discovery
- Scalable & reproducible supply
- Foundation for personalized medicine
Organoids
- Organoids generated from iPSCs
- 3D organ-like tissue models
- Replicate real organ structure & function
- Enable advanced disease modeling
- High predictive accuracy for drug testing
- Customizable for precision medicine research
Join Us in Shaping the Future of Drug Discovery
Partner with us to accelerate breakthroughs using iPSC and AI-powered platforms.
Publications
Greenstone scientists and collaborators regularly publish in peer-reviewed publications to inform the scientific community of discoveries from Greenstone labs and our collaborators.
ADMET-AI Enables Interpretable Predictions of Drug-Induced Cardiotoxicity
Mukherjee S, Swanson K, Walther P, Shivnaraine RV, Leitz J, Pang PD, Zou...
CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity
Liu C, Shen M, Liu Y, Manhas A, Zhao SR, Zhang M, Belbachir...